N4P Stock Price: N4 Pharma PLC holds onto high ground amid coronavirus progress, Phase 3 plans

N4 Pharma PLC's shares have hit 16 pence, doubling from 7.95, the previous closing price. The British company reported promising results in its coronavirus research. LON: NAP continues fluctuating at high volatility.

Update: After closing at 12.50 pence in Tuesday's session – off the peak of 16 but more than 50% up on the day – LONG: N4P continues garnering attention and has room to extend its gains on Wednesday. Investors are eager for anything that helps alleviate the immense health and economic pressures caused by COVID-19. That has sent S&P 500 briefly above its record high.

The pharma firm reported positive COVID-19 Vitro study results using – Nuvex loaded with coronavirus plasmid transfected human embryonic kidney cells in vitro and it induced expression of spike protein cells. 

The company is now advancing directly to the third stage of its COVID-19 project. Shares of pharma firms in the US and in the UK have been surging in response to publications about advances in their coronavirus studies. 

Russian President Vladimir Putin announced his country registered the world's first coronavirus vaccine – yet scientists remain skeptical about the achievement, as it lacks a Phase 3 test. 

N4 Pharma plc share price